Solid Form Informatics For Pharmaceuticals and Fine Chemicals
In this white paper we introduce a knowledge-based approach to improving effectiveness, quality and risk assessment in the development of solid formulations of drugs, agrochemicals and molecular materials.
The cost of failure: We discuss the potential harm that can occur as a result of unaddressed gaps in the understanding of polymorphism in solid form behaviours, especially in late stage development and post product launch, and we review the well-renowned case studies including ritonavir and rotigotine.
Managing risk: We look at ways to manage these risks and improve reliability of solid state development.
The Crystal Form Consortium (CFC) – we discuss how this forum aims to address the lack of rational design tools for solid form development.
The ‘healthcheck’ methodology: We explain how a pro-active evaluation of crystal structures of active ingredients is now routine in a number of organisations.
Benefits of adopting Solid Form Informatics: We look at how it’s possible to prevent potential disasters such as that of ritonavir and rotigotine with Solid Form Informatics.